Skip to main content

Advertisement

Log in

Proliferative and functional aspects of interferon-treated human normal and neoplastic T and B cells

  • Original Article
  • Published:
British Journal of Cancer Submit manuscript

Abstract

Previous studies have shown that normal as well as neoplastic B-cell lines vary substantially in their response to the antiproliferative effects of human interferon (HIF). In this study we took advantage of a recent method to generate long-term continuous normal T-cell cultures (CTC) to investigate the effects of HIF on proliferating lymphoid cells. Normal CTC proved to be resistant to inhibition of proliferation, up to 1000 u HIF had little effect on [3H] TdR uptake, and up to 2000 u HIF had little effect on cell-cycle progression, measured by flow cytometry. Proliferating normal B cells were also resistant to the antiproliferative effect. Nor did up to 500 m HIF inhibit RNA synthesis or immunoglobulin biosynthesis of normal B cells. In contrast, a neoplastic myeloma B cell, a Burkitt's lymphoma cell and a neoplastic leukaemic T cell showed marked inhibition of [3H] TdR uptake and cell cycle progression with as little as 5 u HIF. These results suggest that amounts of HIF sufficient to inhibit proliferation of some neoplastic lymphoid cells have little effect on T- and B-cell proliferation and differentiation of normal B lymphocytes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Attallah, A., Fleisher, T., Khalil, R. et al. Proliferative and functional aspects of interferon-treated human normal and neoplastic T and B cells. Br J Cancer 42, 423–429 (1980). https://doi.org/10.1038/bjc.1980.254

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/bjc.1980.254

  • Springer Nature Limited

Navigation